Lykos Therapeutics details how it is addressing questions raised by FDA advisors during a June 4 advisory meeting and how it will apply these insights to its Risk Evaluation and Mitigation Strategy.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics considers a Risk Evaluation and Mitigation Strategy for MDMA-assisted therapy, both supporters and detractors of MDMA-AT make their case for whether the treatment is safe for patients.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
In the wake of the FDA's rejection of its proposed MDMA-assisted therapy for PTSD, Lykos Therapeutics laid off approximately 100 employees and appointed new leadership while the MAPS nonprofit cut 33% of its workforce.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
The FDA has rejected Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD and requested an additional Phase 3 study.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics awaits an FDA decision this week on its proposed MDMA-assisted therapy for PTSD, the company has announced new initiatives and measures for additional oversight if the therapy is approved.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
